RecruitingNot ApplicableNCT06690736
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Sponsor
Tianjin Medical University
Enrollment
200 participants
Start Date
Mar 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
- F-FDG PET/CT within two weeks
- signed written consent.
Exclusion Criteria3
- pregnancy
- breastfeeding
- known allergy against Pentixafor
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTCXCR4 PET/CT Imaging
Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06690736
Related Trials
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT0686327272 locations
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT071440851 location
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
NCT067543451 location
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study
NCT067870141 location
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
NCT066346281 location